Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

131 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Extending the dosing intervals of nivolumab: model-based simulations in unselected cancer patients.
Puszkiel A, Bianconi G, Pasquiers B, Balakirouchenane D, Arrondeau J, Boudou-Rouquette P, Bretagne MC, Salem JE, Declèves X, Vidal M, Kramkimel N, Guegan S, Aractingi S, Huillard O, Alexandre J, Wislez M, Goldwasser F, Blanchet B. Puszkiel A, et al. Br J Cancer. 2024 May;130(11):1866-1874. doi: 10.1038/s41416-024-02659-x. Epub 2024 Mar 26. Br J Cancer. 2024. PMID: 38532102
Advanced soft-tissue sarcoma in elderly patients: patterns of care and survival.
Garbay D, Maki RG, Blay JY, Isambert N, Piperno Neumann S, Blay C, Zanardi E, Boudou-Rouquette P, Bozec L, Duffaud F, Bertucci F, Italiano A. Garbay D, et al. Ann Oncol. 2013 Jul;24(7):1924-1930. doi: 10.1093/annonc/mdt059. Epub 2013 Mar 13. Ann Oncol. 2013. PMID: 23493135 Free article.
Embryonic signature distinguishes pediatric and adult rhabdoid tumors from other SMARCB1-deficient cancers.
Richer W, Masliah-Planchon J, Clement N, Jimenez I, Maillot L, Gentien D, Albaud B, Chemlali W, Galant C, Larousserie F, Boudou-Rouquette P, Leruste A, Chauvin C, Han ZY, Coindre JM, Varlet P, Freneaux P, Ranchère-Vince D, Delattre O, Bourdeaut F. Richer W, et al. Oncotarget. 2017 May 23;8(21):34245-34257. doi: 10.18632/oncotarget.15939. Oncotarget. 2017. PMID: 28427232 Free PMC article.
Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study.
Duruisseaux M, Besse B, Cadranel J, Pérol M, Mennecier B, Bigay-Game L, Descourt R, Dansin E, Audigier-Valette C, Moreau L, Hureaux J, Veillon R, Otto J, Madroszyk-Flandin A, Cortot A, Guichard F, Boudou-Rouquette P, Langlais A, Missy P, Morin F, Moro-Sibilot D. Duruisseaux M, et al. Oncotarget. 2017 Mar 28;8(13):21903-21917. doi: 10.18632/oncotarget.15746. Oncotarget. 2017. PMID: 28423535 Free PMC article.
Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study.
Duffaud F, Mir O, Boudou-Rouquette P, Piperno-Neumann S, Penel N, Bompas E, Delcambre C, Kalbacher E, Italiano A, Collard O, Chevreau C, Saada E, Isambert N, Delaye J, Schiffler C, Bouvier C, Vidal V, Chabaud S, Blay JY; French Sarcoma Group. Duffaud F, et al. Lancet Oncol. 2019 Jan;20(1):120-133. doi: 10.1016/S1470-2045(18)30742-3. Epub 2018 Nov 23. Lancet Oncol. 2019. PMID: 30477937 Clinical Trial.
131 results